Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals

Sponsor

University of California, San Diego (Other)

Overall Status

Completed

CT.gov ID

NCT03086200

Collaborator

University of Southern California (Other), Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (Other), Los Angeles LGBT Center (Other), Family Health Centers of San Diego (Other)

263

Enrollment

Locations

Arms

41.9

Actual Duration (Months)

52.6

Patients Per Site

1.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

CCTG 603 is an open-label, two-arm, randomized (1:1) clinical demonstration project to determine if brief Motivational Interviewing (MI-B) added to a text-message based adherence intervention (iTAB) improves adherence to PrEP among transgender persons.

Condition or Disease	Intervention/Treatment	Phase
Patient Adherence HIV Seronegativity	Behavioral: brief Motivational Interviewing	N/A

Detailed Description

A total of 300 HIV-uninfected transgender or gender non-conforming individuals, defined as currently identifying as a gender different from sex assigned at birth, with high-risk transmission behavior will be enrolled into this study. Each participant will be followed for a maximum of 48 weeks after enrollment. The primary endpoint will be measured at 48 weeks, or the last week on study if the participant is discontinued early.

All participants will start PrEP with TDF / FTC fixed dose combination taken once daily. Subjects will be randomized (1:1) to the iTAB text messaging adherence reminder intervention either with or without brief motivational interviewing (MI-b) for suboptimal adherence. All participants will receive the iTAB system to provide personalized, automated text messages to support and monitor adherence. In the MI-b arm, poor adheres by iTAB reporting will receive targeted MI-b via telephone.

Both groups will receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening.

Study Design

Study Type:

Interventional

Actual Enrollment :

263 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Prevention

Official Title:

CCTG 603: Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals (The iM-PrEPT Study)

Actual Study Start Date :

Jun 23, 2017

Actual Primary Completion Date :

Sep 30, 2020

Actual Study Completion Date :

Dec 18, 2020

Arms and Interventions

Arm	Intervention/Treatment
No Intervention: iTAB + SOC Control Arm Participants will receive PrEP and standard of care (SOC) including health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psychosocial barriers, and adherence counseling. In addition to SOC, participants will receive daily text messages (iTAB) as reminders for medication adherence. Text messages will be setup during the Baseline visit in coordination with the participant's preferences.
Experimental: iTAB + MI-b Intervention Arm Participants will receive the same PrEP, SOC procedures, and iTAB support as that of the Control Arm. Participants in the Intervention Arm will also receive brief motivational interviewing counseling sessions if adherence becomes suboptimal. Adherence will be monitored by responses to the iTAB system; if Intervention Arm participants reply with 3 consecutive negative or non-responses, MI-b counselors will perform 15-minute over-the-phone motivational interviewing counseling sessions with the participant.	Behavioral: brief Motivational Interviewing All study participants will receive daily dosing text message reminders. Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule.

Arm

Intervention/Treatment

No Intervention: iTAB + SOC Control Arm

Participants will receive PrEP and standard of care (SOC) including health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psychosocial barriers, and adherence counseling. In addition to SOC, participants will receive daily text messages (iTAB) as reminders for medication adherence. Text messages will be setup during the Baseline visit in coordination with the participant's preferences.

Experimental: iTAB + MI-b Intervention Arm

Participants will receive the same PrEP, SOC procedures, and iTAB support as that of the Control Arm. Participants in the Intervention Arm will also receive brief motivational interviewing counseling sessions if adherence becomes suboptimal. Adherence will be monitored by responses to the iTAB system; if Intervention Arm participants reply with 3 consecutive negative or non-responses, MI-b counselors will perform 15-minute over-the-phone motivational interviewing counseling sessions with the participant.

Behavioral: brief Motivational Interviewing

All study participants will receive daily dosing text message reminders. Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule.

Outcome Measures

Primary Outcome Measures

PrEP Adherence [Baseline up to Week 48]
To compare adherence to fixed dose TDF/FTC, as measured by intracellular levels of TFV-DP > 1246 fmol/punch, between subjects randomized to receive iTAB with versus without brief Motivational Interviewing, when used for adherence support to pre-exposure prophylaxis among transgender individuals at elevated risk for HIV acquisition.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Transgender identity, defined as identifying differently from sex assigned at birth
Age 18 years or older
Risk of acquisition of HIV as evident by one or more of the following:

Has at least one HIV infected sexual partner for ≥4 weeks

OR,

Anticipated or concern of unprotected anal or vaginal sex with a partner in the next 3 months

OR,

Any partner in the past 12 months AND at least one of the following:

any condomless anal or vaginal sex in the past 12 months
any STI diagnosed or reported in the past 12 months
exchange of money, gifts, shelter, or drugs for sex

OR,

PEP-use in the past 12 months

Negative for HIV infection by nucleic acid test (NAT) or other sensitive method such as 4th generation antigen/antibody test
Acceptable renal function as measured by calculated creatinine clearance of at least 60 mL/min by the Cockcroft-Gault formula (eCcr (male) in mL/min = [(140 - age in years) x (lean body weight in kg)] / (72 x serum creatinine in mg/dL) in the past 30 days

Exclusion Criteria:

Unable to give informed consent
Active hepatitis B defined by a positive hepatitis B surface antigen (HBsAg)
Substantial medical condition that, in the opinion of the investigator, would preclude participation, as defined by
gastrointestinal condition that would impair absorption of study drugs
known condition of reduce bone density (e.g. osteoporosis or osteogenesis imperfect) that significantly elevate the risk of bone fracture
neurological or severe psychiatric condition that would significantly impair the ability to adhere to PrEP
tubular or glomerular kidney disease that could be exacerbated by tenofovir
other medical condition that would unacceptably increase the risk of harm from study drug or significantly impair the ability to adhere to PrEP
Suspected sensitivity or allergy to the study drug or any of its components
Currently using an essential product or medication that interacts with the study drug such as the following:
other antiretroviral agent (including nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors or investigational antiretroviral agents) - if currently on TDF/FTC for PEP or PrEP they can switch to study provided drug but can not continue any other antiretroviral agent
agents with known nephrotoxic potential:
aminoglycoside antibiotics (including gentamicin)
IV amphotericin B
cidofovir
cisplatin
foscarnet
IV pentamidine
IV vancomycin
oral or IV gancyclovir
other agents with significant nephrotoxic potential
drugs that slow renal excretion
probenecid
immune system modulators
systemic chemotherapeutic agents (i.e. cancer treatment medications)
ongoing systemic corticosteroids (with the exception of short courses of tapering steroid doses for asthma or other self- limited condition).
interleukin-2 (IL-2)
interferon (alpha, beta, or gamma)
other agent known to have a significant interaction with TDF or FTC
Proteinuria 2+ or greater by urine dipstick
Pregnancy (if individual has a uterus)
Other condition that, in the opinion of the investigator, would put the participant at risk, complicate interpretation of study outcome data, or would otherwise interfere with participation or achieving the study objectives

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Los Angeles Lesbian, Gay, Bisexual, and Transgender Center	Los Angeles	California	United States	90027
2	University of Southern California	Los Angeles	California	United States	90033
3	Family Health Centers of San Diego	San Diego	California	United States	92103
4	University of California, San Diego	San Diego	California	United States	92103
5	LA Biomed at Harbor-UCLA	Torrance	California	United States	90502